In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 301 to 325 of 373

Sort by

Type: Guidance`Remove $Type: Guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]	Technology appraisal guidance	TBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6757]	Technology appraisal guidance	13 May 2027
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]	Technology appraisal guidance	TBC
Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessment	HealthTech guidance	15 September 2026
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091]	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632]	Technology appraisal guidance	TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]	Technology appraisal guidance	8 July 2026
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]	Technology appraisal guidance	21 April 2021
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]	Technology appraisal guidance	TBC
Staged bilateral MRI-guided focused ultrasound thalamotomy for medication-refractory essential tremor	HealthTech guidance	17 December 2026
Sugemalimab with chemotherapy for untreated advanced non-small-cell lung cancer [ID6758]	Technology appraisal guidance	TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]	Technology appraisal guidance	TBC
Surgical mesh for treatment of non-primary ventral hernias	HealthTech guidance	TBC
Surgical mesh for treatment of primary ventral hernias	Health technology evaluation	3 February 2027
Surgical vessel sealing systems (MT798)	Medical technologies guidance	TBC
Suspected sepsis in pregnancy: recognition, diagnosis and early management	NICE guideline	17 February 2027
Suspected sepsis in under 16s: recognition, diagnosis and early management	NICE guideline	17 February 2027
Suspected sepsis: recognition, diagnosis and early management	NICE guideline	TBC
Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing	NICE guideline	11 September 2026
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]	Technology appraisal guidance	10 June 2027
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]	Technology appraisal guidance	TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]	Technology appraisal guidance	TBC
Tarlatamab for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]	Technology appraisal guidance	13 January 2027
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401]	Technology appraisal guidance	TBC

Results per page

10
25
50
All